We look forward to sharing data at the 2024 ESMO - European Society for Medical Oncology Congress, highlighting the critical role liquid biopsy plays in informing therapy selection and the strong performance of our precision oncology technology in multiple advanced tumor types. Press release and presentation details: https://bit.ly/4daVwPv #ESMO24
Guardant Health
Biotechnology Research
Palo Alto, California 180,126 followers
Conquering Cancer With Data
About us
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield™ test, aims to address the needs of individuals eligible for cancer screening.
- Website
-
https://guardanthealth.com/
External link for Guardant Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2012
Locations
Employees at Guardant Health
Updates
-
Via The Washington Post: Advancements in screening technologies, such as our Shield blood test, have the potential to revolutionize cancer care. However, the path to equitable access remains uncertain. It’s essential that policymakers address these barriers to fulfill the promise of better preventive care for all.
-
We’re pleased to announce our partnership with Fondazione Policlinico Universitario Agostino Gemelli IRCCS, establishing one of the first hospital-based liquid biopsy testing facilities in Italy. Our co-CEO Helmy Eltoukhy: “We’re thrilled to partner with Policlinico Gemelli, empowering clinicians to swiftly detect tumor alterations with a blood test, guiding personalized treatments, and fueling research innovation. This collaboration brings us closer to our mission of ensuring all cancer patients worldwide have access to the latest advancements for optimal care.”
Guardant and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
investors.guardanthealth.com
-
Join us next Wednesday at the 14th Annual World Clinical Biomarkers & Companion Diagnostics Summit for an engaging plenary session led by Sara Wienke MS, CGC on enhancing the predictive power of liquid biopsy with a methylation-based approach to treatment response monitoring. More details: https://world-cdx.com/
-
Discover the work behind our mission to conquer cancer with data as part of the Global Health documentary series, which spotlights innovative solutions to global health issues. Explore the full documentary and interview featured on Reuters: https://bit.ly/3AKUdJR
-
By ringing this morning's bell, we celebrate another pivotal moment in our journey to conquer cancer with data with the FDA approval and commercial launch of our Shield blood test! Thank you to our dedicated team, partners, and supporters who have made this achievement possible. Watch the opening ceremony: https://lnkd.in/gRGepS_c
📊 Conquering cancer through data. 🥼 Guardant Health is a leading precision medicine company, addressing the needs of individuals eligible for cancer screening. 🎉 So thrilled to celebrate the FDA approval of your Shield blood test for colorectal cancer, $GH!
-
Today we announced that we will proudly ring the Nasdaq opening bell on August 28 to celebrate the launch of our Shield blood test for colorectal cancer screening. “We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after we first rang the bell for our IPO,” - co-CEO AmirAli Talasaz. Watch the bell ringing live next Wednesday at 8:30am ET: https://bit.ly/470NlnO
Guardant to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
investors.guardanthealth.com
-
Last week, our teams came together for a fantastic “Making History” event, where we celebrated two major milestones: the upgrade of Guardant360 on our Infinity platform and the FDA approval of our Shield blood test. A heartfelt THANK YOU to every Guardant employee. Your dedication and teamwork are the driving force behind our success. As AmirAli Talasaz shared, while each of our roles may vary, our collective innovation, grit, and courage shine brightest when we unite as #OneGuardant.
-
+1
-
Our oncology sales team is growing! https://bit.ly/3SIotej At Guardant Health, our cutting-edge solutions place us at the forefront of cancer care. As we continue to make significant breakthroughs with our market-leading liquid biopsy testing, we’re expanding our presence across several U.S. regions. We’re looking for passionate sales professionals who embrace our patient-first approach to help individuals receive the right treatment plan. Sound exciting? #JoinGuardant and help us conquer cancer with data!
-
A more pleasant way to screen for colon cancer deserves a pleasant website experience. Introducing ShieldCancerScreen.com—your go-to source to learn more about Shield and access valuable resources. Explore how we’re transforming #ColorectalCancer screening with our FDA-approved Shield test today!
Similar pages
Browse jobs
Stock
GH
NASDAQ
20 minutes delay
$25.39
0.31 (1.236%)
- Open
- 25.46
- Low
- 25.24
- High
- 26.19
Data from Refinitiv
See more info on